Rebamipide, a Cytoprotective Drug, Increases Gastric Mucus Secretion in Human: Evaluations with Endoscopic Gastrin Test

• DOI: 10.1007/s10620-008-0507-4
• Publication Date: 2008-10-30T21:44:26Z
• Authors: Katsunori Iijima; T. Ichikawa; S. Okada; M. Ogawa; T. Koike; S. Ohara; T. Shimosegawa
• Keywords: Adult; Male; 0301 basic medicine; Alanine; Gastric Juice; Helicobacter pylori; Physiology; Gastroenterology; Mucins; Middle Aged; Quinolones; Anti-Ulcer Agents; Chromatography, Ion Exchange; Endoscopy, Gastrointestinal; Helicobacter Infections; 03 medical and health sciences; Gastric Mucosa; Gastrins; Humans; Original Article; Female

We have previously developed a rapid, simple endoscopic method for evaluating gastrin-stimulated maximal acid output (the endoscopic gastrin test, EGT). In EGT, gastric fluid newly secreted over 10 min after gastrin stimulation is collected under direct endoscopic visualization. In this study, employing the EGT, we evaluated the effect of rebamipide, a cytoprotective anti-ulcer drug, on gastric mucus secretion. In ten Helicobacter pylori-negative healthy volunteers, gastric juice was collected by EGT prior to and after 4-week administration of rebamipide. The collected gastric juice was subjected to analysis for gastric mucus output. Total gastric mucin output was significantly increased by 53% by rebamipide administration from 3.2 +/- 1.2 mg hexose/10 min to 4.9 +/- 2.2 mg hexose/10 min (P < 0.01). Further analysis by ion-exchange chromatography revealed that rebamipide administration induced a specific increase in acidic mucin rich in sialic acid. Applying EGT, this study demonstrated that rebamipide administration increased gastric mucus secretion in human.